Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Open Label Phase II Study of Pomalidomide and Dexamethasone in Relapse and Refractory Multiple Myeloma Patients Who Are Progressive and Did Not Achieve at Least a Partial Response to Bortezomib and Lenalidomide

NCT01053949 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT01053949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01053949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Open Label Phase II Study of Pomalidomide and Dexamethasone in Relapse and Refractory Multiple Myeloma Patients Who Are Progressive and Did Not Achieve at Least a Partial Response to Bortezomib and Lenalidomide
Lead sponsor
University Hospital, Lille
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
April 30, 2015
Enrollment
84 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma